Physicians Struggle With Antiquated Reimbursement for Next-Generation Testing

Tony Berberabe, MPH @OncBiz_Wiz
Published: Friday, May 22, 2015
Richard L. Schilsky, MD

Richard L. Schilsky, MD

The growing use of genetic biomarker tests to screen, monitor, diagnose, and treat patients with cancer has the potential to improve outcomes and reduce costs (Table), but payment systems for covering and reimbursing for these tests have fallen behind the times.

Alvin Martin, MD

Tissue Limitations Make Comprehensive Testing More Practical

Table. Use and Potential Economic Value of Cancer Biomarkers

Source: Schneider JE, Sidhu MK, Doucet C, et al. Economics of cancer biomarkers. Per Med. 2012;8:829-837.

... to read the full story
To Read the Full Story

View Conference Coverage
OncLive SAP
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Oncology Nursing News
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
OncLive Resources

Conference Coverage
OncLive TV
Peer Exchange
Web Exclusives

About Us
Advisory Board
Contact Us
Forgot Password
Press Releases
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-939-0221

Copyright OncLive 2006-2019
Intellisphere, LLC. All Rights Reserved.